News and Trends 22 Mar 2019 Danish Startup Gets €5.5M to Produce Hard-to-Make Chemicals Through Fermentation CysBio is developing a fermentation technology to produce valuable chemicals that were previously too difficult or expensive to make. Founded just at the beginning of this year, CysBio is now receiving its first funding. This seed investment comes from the Chinese chemical company Zhejiang NHU, which has also established a partnership to commercialize some of […] March 22, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Mar 2019 Celgene and Exscientia Sign the Largest Deal in AI for Drug Discovery In a deal with €22M paid upfront and undisclosed “substantial milestones and royalties,” Exscientia will use its artificial intelligence technology to help Celgene speed up the discovery of drug candidates for cancer and autoimmune diseases. “It is the largest AI drug discovery deal done in the industry to date,” said Andrew Hopkins, CEO of Oxford-based […] March 21, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Mar 2019 UK Government’s Bid on Healthcare Genomics Already Benefiting Biotechs The positive stance of the UK Government towards incorporation of genomics into healthcare has created unparalleled chances for the country’s biotech companies, which are already taking advantage of the business opportunities. Following the completion of the 100,000 Genomes Project at the end of 2018, the fledgling NHS Genomic Medicine Service launched. This service aims to […] March 21, 2019 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 20 Mar 2019 Czech Cell Therapy Increases Survival in Ovarian Cancer by 62% The Czech biotech company Sotio has shown in a phase II trial that its cellular immunotherapy can decrease the risk of a patient dying from ovarian cancer by 62%. The cell therapy was tested in people with the most severe stages of recurrent ovarian cancer, in combination with second-line chemotherapy when cancer returned after […] March 20, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 20 Mar 2019 Unlocking the Potential of Fast DNA Synthesis While the price and speed of reading DNA have dropped massively, writing DNA fast and affordably still remains a challenge. Philip talked to Sylvain Gariel, COO of the French company DNA Script, who strives to reinvent DNA synthesis. DNA has become a basic necessity in any biology lab. Thanks to new technologies we can now […] March 20, 2019 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Mar 2019 Shares Drop 40% as Allergy Therapeutics Announces Failed Phase III Trial Allergy Therapeutics has revealed that its immunotherapy for birch pollen allergy did not result in a significant symptom improvement when compared to a placebo. As a direct result of the announcement, the shares of Allergy Therapeutics on the London Stock Exchange dropped over 40% within two hours. The phase III trial enrolled 582 people across […] March 18, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 18 Mar 2019 The Search for a Better Biofuel: Can Biotech Deliver? With dire climate change reports landing one after another in 2018 the need for sustainable, scalable, and affordable biofuels to aid in this transition to a more sustainable future has never been greater. Ticking all three boxes is no easy task, but the biotech sector has several promising solutions in development. Producing carbon-neutral fuels from […] March 18, 2019 - 7 minutesmins - By Farhan Mitha Share WhatsApp Twitter Linkedin Email
Startup Scout 15 Mar 2019 This Biotech Wants You to Age Well Age is a risk factor in many diseases, such as cancer and heart disease. The UK biotech Samsara Therapeutics thinks that it can make drugs that can prevent multiple conditions at once by targeting the aging process itself. Mission: To develop drugs that target the biological mechanisms underlying aging. Slowing the aging process seems like […] March 15, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 14 Mar 2019 Microsoft Aims to Make Cell Therapies Cheaper with Artificial Intelligence Microsoft has launched a collaboration with the UK company Oxford BioMedica to use Microsoft’s artificial intelligence technology to make gene and cell therapy manufacturing easier and cheaper. Genetically programming cells and viruses to make cell and gene therapies is not as simple as programming a computer. Organisms have many layers of complexity and unpredictability, sometimes […] March 14, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 13 Mar 2019 Artificial Intelligence Detects Juvenile Arthritis in the Blood Using artificial intelligence, a Belgian research group can diagnose juvenile arthritis from blood samples with almost 90% accuracy and identify different forms of the disease, something that is not currently possible. Juvenile idiopathic arthritis causes joint pain, swelling and stiffness in children under the age of 16. The disease is hard to treat because there […] March 13, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 12 Mar 2019 Stem Cells and Hydrogel Make Potential Osteoarthritis Treatment Scientists from the Netherlands have received a €600,000 grant to test a treatment for osteoarthritis in humans that combines hydrogels and stem cells to help the knee joint heal. In osteoarthritis, the cartilage in joints such as the knees breaks down, causing stiffness and pain. There is no cure at the moment, and most current […] March 12, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 12 Mar 2019 Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis An antibody that blocks the action of a hidden viral protein encoded by our genome shows encouraging signs of slowing down the progression of multiple sclerosis, according to the Swiss biotech GeNeuro which carried out the research. GeNeuro’s monoclonal antibody drug targets the hidden viral protein because it’s linked to the occurrence of multiple sclerosis, […] March 12, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email